Immunocore turns to Oncobit platform

The British biotechnology company Immunocore will in future make use of the platform developed by Oncobit, a medtech firm and spin-off from the University of Zurich. The tests carried out via this platform allow specific cancer markers to be quantified in clinical trials.

Immunocore will utilize a platform developed by the medtech firm Oncobit.
Immunocore will utilize a platform developed by the medtech firm Oncobit. Generic image: Herney/Pixabay

Oncobit, the medtech firm based in Schlieren in the canton of Zurich, has concluded a service agreement with the British biotechnology company Immunocore. The partnership between the two companies will seek to improve the use and understanding of circulating tumor DNA (ctDNA) analysis as a reliable, real-time therapy response marker in clinical trials, further details of which can be found in a press release.

To this end, the British company, which focuses on the development and provision of innovative immunomodulating medicines and has operated a branch office in Risch-Rotkreuz in the canton of Zug since 2022, will in future rely on the digital platform developed by the spin-off from the University of Zurich. According to information from the company itself, the platform offers a unique combination of proprietary digital PCR (Polymerase Chain Reaction) assays and software.

PCR is a laboratory technique for quickly producing millions or even billions of copies of a specific section of DNA, which can then be examined in more detail. According to the press release, Oncobit’s aim is to optimize therapy management and transform cancer care in a cost and time-efficient manner by quantifying specific cancer markers in liquid biopsies.

“We are excited to collaborate with Immunocore, a company that shares our vision for innovation in pioneering cancer care”, as Dr. Claudia Scheckel, CEO of Oncobit, explains in the press release. She adds: “By contributing to such studies, we are proud to work towards our goal of improving patient outcomes with high-precision and cutting-edge cancer monitoring solutions.” 

Handbook for Investors

Our Handbook for Investors provides valuable information about technologies and production costs, taxes and financing, as well as the legal system and infrastructure in Switzerland. Browse through the complete handbook online or download the chapters most relevant to you.


Official program